PELL Bio-Med Technology Co Ltd 6949
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- TWD 82.00
- Day Range
- TWD 80.70–81.20
- 52-Week Range
- TWD 70.60–178.50
- Bid/Ask
- TWD 80.70 / TWD 82.80
- Market Cap
- TWD 4.61 Bil
- Volume/Avg
- 11,000 / 26,730
Key Statistics
- Price/Earnings (Normalized)
- 1.77
- Price/Sales
- 14.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 93
- Website
- https://www.pellbmt.com
Comparables
Valuation
|
Metric
|
6949
|
6712
|
6586
|
|---|---|---|---|
Price/Earnings (Normalized) | 1.77 | 38.13 | — |
Price/Book Value | 3.40 | 9.61 | 4.17 |
Price/Sales | 14.24 | 18.16 | — |
Price/Cash Flow | — | 34.21 | — |
Price/Earnings
6949
6712
6586
Financial Strength
|
Metric
|
6949
|
6712
|
6586
|
|---|---|---|---|
Quick Ratio | 7.13 | 3.17 | 23.03 |
Current Ratio | 7.21 | 3.65 | 23.43 |
Interest Coverage | −177.25 | 3,803.58 | −730.54 |
Quick Ratio
6949
6712
6586
Profitability
|
Metric
|
6949
|
6712
|
6586
|
|---|---|---|---|
Return on Assets (Normalized) | −19.55% | 18.39% | −10.40% |
Return on Equity (Normalized) | −24.51% | 20.77% | −10.99% |
Return on Invested Capital (Normalized) | −21.54% | 20.22% | −12.17% |
Return on Assets
6949
6712
6586
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kzmckzxdb | Rbx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zdnvpzhbq | Bkqxmpl | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dsczpbtnp | Hdwwlvb | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mxrknvlj | Vpqbvr | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Gsbxmvgh | Myxm | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Ywhpfcxg | Lkmjj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Lndfhvst | Qjvwc | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xkjkttld | Lrtk | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hwpqhfbs | Vysyxdh | $13.2 Bil | |||
| Incyte Corp
INCY
| Tclszxq | Wghpvc | $13.0 Bil |
United States